by Pascal Gervaz and C. Fontolliet
Neovessel formation is a pre-requisite for tumour growth and dissemination. Inhibition of angiogenesis is a promising approach for the treatment of neoplasms. In recent years, antiangiogenic drugs, such as TNP-470, have entered clinical trials. In this paper, we review the key experimental and clinical data on the role of TNP-470 in anti-tumour treatment.
The fulll text of this article can be found here
in International Journal Experimental Pathology 1998 December; 79(6): 359–362. doi: 10.1046 /j. 1365-2613. 1998.00087.x